Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Akebia Ther (AKBA)

NASDAQ
Currency in USD
Disclaimer
1.320
+0.040(+3.13%)
Closed
After Hours
1.3200.000(0.00%)
AKBA Scorecard
Full Analysis
2 analysts have revised their earnings upwards for the upcoming period
Fair Value
Day's Range
1.2701.320
52 wk Range
0.7802.480
Prev. Close
1.28
Open
1.28
Day's Range
1.27-1.32
52 wk Range
0.78-2.48
Volume
1,312,005
Average Vol. (3m)
1,796,277
1-Year Change
25.49%
Book Value / Share
Unlock
Fair Value
Unlock
Fair Value Upside
Unlock
AKBA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
5.500
Upside
+316.667%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year
Show more

Akebia Ther Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Compare AKBA to Peers and Sector

Metrics to compare
AKBA
Peers
Sector
Relationship
P/E Ratio
−6.8x−1.3x−0.6x
PEG Ratio
−0.110.000.00
Price / Book
−8.2x0.7x2.6x
Price / LTM Sales
1.6x12.6x3.2x
Upside (Analyst Target)
290.6%208.8%48.5%
Fair Value Upside
Unlock7.8%7.8%Unlock

People Also Watch

8.290
PTEN
+2.73%
235.65
PI
+1.70%
0.3883
WTO
-2.34%
17.1450
ADMA
+0.79%

FAQ

What Is the Akebia Ther (AKBA) Stock Price Today?

The Akebia Ther stock price today is 1.32

What Stock Exchange Does Akebia Ther Trade On?

Akebia Ther is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Akebia Ther?

The stock symbol for Akebia Ther is "AKBA."

What Is the Akebia Ther Market Cap?

As of today, Akebia Ther market cap is 277.58M.

What is Akebia Ther Earnings Per Share?

The Akebia Ther EPS is -0.204.

What Is the Next Akebia Ther Earnings Date?

Akebia Ther will release its next earnings report on Nov 07, 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.